<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04530487</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0496</org_study_id>
    <secondary_id>NCI-2020-05879</secondary_id>
    <secondary_id>2020-0496</secondary_id>
    <nct_id>NCT04530487</nct_id>
  </id_info>
  <brief_title>Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults</brief_title>
  <official_title>A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric and Adolescent-Young Adults Patients With High Risk Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial investigates side effects and how well donor stem cell transplant after&#xD;
      chemotherapy works in treating pediatric and adolescent-young adults with high-risk solid&#xD;
      tumor that has come back (recurrent) or does not respond to treatment (refractory).&#xD;
      Chemotherapy drugs, such as fludarabine, thiotepa, etoposide, melphalan, and rabbit&#xD;
      anti-thymocyte globulin work in different ways to stop the growth of tumor cells, either by&#xD;
      killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving&#xD;
      chemotherapy before a donor stem cell transplant helps kill cancer cells in the body and&#xD;
      helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to&#xD;
      grow. When the healthy stem cells from a donor are infused into a patient, they may help the&#xD;
      patient's bone marrow make more healthy cells and platelets and may help destroy any&#xD;
      remaining cancer cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To assess tolerability of allogeneic hematopoietic stem cell transplantation (HCT) for&#xD;
      patients with chemo-responsive recurrent/refractory solid tumors as defined by&#xD;
      transplant-related mortality (TRM) at day 30 and the rate of grade III or higher organ&#xD;
      toxicity (Bearman Regimen-Related Toxicities Scale) attributable to conditioning occurring&#xD;
      within 30 days.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Assess median time to platelet and neutrophil engraftment. II. Assess incidence of acute&#xD;
      graft-versus-host disease (aGVHD) by day 100. III. Assess incidence of chronic GVHD (cGVHD)&#xD;
      at day 100 and one year. IV. Assess rate of grade II organ toxicity through day 100. V.&#xD;
      Assess rate of graft failure (primary and secondary) through day 100. VI. Assess rate of&#xD;
      infectious complications through day 100. VII. Assess progression free survival (PFS) at day&#xD;
      100,180 and 365. VIII. Assess cumulative incidence of relapse, overall survival (OS) at 100&#xD;
      days and 1 year.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      CONDITIONING REGIMEN: Patients receive thiotepa intravenously (IV) over 2-4 hours and&#xD;
      etoposide IV over 60 minutes on days -8 to -6, melphalan IV over 20 minutes on days -5 and&#xD;
      -4, and fludarabine phosphate IV over 1 hour on days -5 to -3 in the absence of disease&#xD;
      progression or unacceptable toxicity. Patients receiving umbilical cord transplant also&#xD;
      receive rabbit anti-thymocyte globulin IV on days -4 and -3.&#xD;
&#xD;
      TRANSPLANT: Patients undergo HSCT on day 0.&#xD;
&#xD;
      GVHD PROPHYLAXIS: Beginning day -2, patients receive tacrolimus or cyclosporine IV&#xD;
      continuously until able to receive orally (PO). Patients continue tacrolimus or cyclosporine&#xD;
      PO to day 60 and tapered to day 100. Patients also receive mycophenolate mofetil PO or IV&#xD;
      every 8 hours until day 40 and tapered to day 90.&#xD;
&#xD;
      After completion of HSCT, patients are followed up for up to 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2020</start_date>
  <completion_date type="Anticipated">May 9, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 9, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transplant-related mortality (TRM)</measure>
    <time_frame>At 30 days</time_frame>
    <description>The proportion of patients with 30-day TRM will be reported together with the corresponding 95% Bayesian credible interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of grade III or higher organ toxicity attributable to conditioning</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Assessed using the Bearman Regimen-Related Toxicities Scale. The proportion of patients with 30-day grade III or higher organ toxicity will be reported together with the corresponding 95% Bayesian credible interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to platelet and neutrophil engraftment</measure>
    <time_frame>Up to 1 year post transplant</time_frame>
    <description>Will be calculated and illustrated from the time of transplant by the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute graft versus host disease (aGVHD)</measure>
    <time_frame>At 100 days post transplant</time_frame>
    <description>The 100-day rates of acute with the competing risk of relapse will be estimated using the method of Gooley.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GVHD</measure>
    <time_frame>At 100 days post transplant</time_frame>
    <description>The 100-day rates of chronic GVHD with the competing risk of relapse will be estimated using the method of Gooley</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic GVHD</measure>
    <time_frame>At 1 year post transplant</time_frame>
    <description>The 1 year rates of chronic GVHD with the competing risk of relapse will be estimated using the method of Gooley.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of grade II organ toxicity</measure>
    <time_frame>Up to 100 days post transplant</time_frame>
    <description>The 100-day rates of grade II organ toxicity will be reported as counts with percentages.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of graft failure (primary and secondary)</measure>
    <time_frame>Up to 100 days post transplant</time_frame>
    <description>The 100-day rates of primary and secondary graft failure will be reported as counts with percentages.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of infectious complications</measure>
    <time_frame>Up to 100 days post transplant</time_frame>
    <description>The 100-day rates of infectious complications will be reported as counts with percentages.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>At 180 days post transplant</time_frame>
    <description>Will be assessed using the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>At 100 days post transplant</time_frame>
    <description>Will be calculated and illustrated from the time of transplant by the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>At 1 year post transplant</time_frame>
    <description>Will be calculated and illustrated from the time of transplant by the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of relapse</measure>
    <time_frame>At 100 days post transplant</time_frame>
    <description>Will be calculated and illustrated from the time of transplant by the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of relapse</measure>
    <time_frame>At 1 year post transplant</time_frame>
    <description>Will be calculated and illustrated from the time of transplant by the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>At 100 days post transplant</time_frame>
    <description>Will be calculated and illustrated from the time of transplant by the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>At 1 year post transplant</time_frame>
    <description>Will be calculated and illustrated from the time of transplant by the method of Kaplan and Meier.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Desmoplastic Small Round Cell Tumor</condition>
  <condition>Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor</condition>
  <condition>Recurrent Desmoplastic Small Round Cell Tumor</condition>
  <condition>Recurrent Malignant Peripheral Nerve Sheath Tumor</condition>
  <condition>Recurrent Malignant Solid Neoplasm</condition>
  <condition>Recurrent Neuroblastoma</condition>
  <condition>Recurrent Rhabdomyosarcoma</condition>
  <condition>Refractory Desmoplastic Small Round Cell Tumor</condition>
  <condition>Refractory Malignant Peripheral Nerve Sheath Tumor</condition>
  <condition>Refractory Malignant Solid Neoplasm</condition>
  <condition>Refractory Neuroblastoma</condition>
  <condition>Refractory Rhabdomyosarcoma</condition>
  <arm_group>
    <arm_group_label>Treatment (conditioning regimen, HSCT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CONDITIONING REGIMEN: Patients receive thiotepa IV over 2-4 hours, etoposide IV over 60 minutes on days -8 to -6, melphalan IV over 20 minutes on days -5 and -4, and fludarabine phosphate IV over 1 hour on days -5 to -3 in the absence of disease progression or unacceptable toxicity. Patients receiving umbilical cord transplant also receive rabbit anti-thymocyte globulin IV on days -3 and -4.&#xD;
TRANSPLANT: Patients undergo HSCT on day 0.&#xD;
GVHD PROPHYLAXIS: Beginning day -2, patients receive tacrolimus or cyclosporine IV continuously until able to receive PO. Patients continue tacrolimus or cyclosporine PO to day 60 and tapered to day 100. Patients also receive mycophenolate mofetil PO or IV every 8 hours until day 40 and tapered to day 90.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo HSCT</description>
    <arm_group_label>Treatment (conditioning regimen, HSCT)</arm_group_label>
    <other_name>Allogeneic Hematopoietic Cell Transplantation</other_name>
    <other_name>Allogeneic Stem Cell Transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
    <other_name>Stem Cell Transplantation, Allogeneic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Given IV and PO</description>
    <arm_group_label>Treatment (conditioning regimen, HSCT)</arm_group_label>
    <other_name>27-400</other_name>
    <other_name>Ciclosporin</other_name>
    <other_name>CsA</other_name>
    <other_name>Cyclosporin</other_name>
    <other_name>Cyclosporin A</other_name>
    <other_name>Cyclosporine Modified</other_name>
    <other_name>Gengraf</other_name>
    <other_name>Neoral</other_name>
    <other_name>OL 27-400</other_name>
    <other_name>Sandimmune</other_name>
    <other_name>SangCya</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (conditioning regimen, HSCT)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
    <other_name>VP16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (conditioning regimen, HSCT)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lapine T-Lymphocyte Immune Globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (conditioning regimen, HSCT)</arm_group_label>
    <other_name>Anti-Thymocyte Globulin Rabbit</other_name>
    <other_name>Grafalon</other_name>
    <other_name>Rabbit Anti-Human Thymocyte Globulin (RATG)</other_name>
    <other_name>Rabbit Anti-Thymocyte Globulin</other_name>
    <other_name>Rabbit Antithymocyte Globulin</other_name>
    <other_name>Rabbit ATG</other_name>
    <other_name>rATG</other_name>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (conditioning regimen, HSCT)</arm_group_label>
    <other_name>Alanine Nitrogen Mustard</other_name>
    <other_name>CB-3025</other_name>
    <other_name>L-PAM</other_name>
    <other_name>L-Phenylalanine Mustard</other_name>
    <other_name>L-Sarcolysin</other_name>
    <other_name>L-Sarcolysin Phenylalanine mustard</other_name>
    <other_name>L-Sarcolysine</other_name>
    <other_name>Melphalanum</other_name>
    <other_name>Phenylalanine Mustard</other_name>
    <other_name>Phenylalanine Nitrogen Mustard</other_name>
    <other_name>Sarcoclorin</other_name>
    <other_name>Sarkolysin</other_name>
    <other_name>WR-19813</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (conditioning regimen, HSCT)</arm_group_label>
    <other_name>CellCept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV and PO</description>
    <arm_group_label>Treatment (conditioning regimen, HSCT)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (conditioning regimen, HSCT)</arm_group_label>
    <other_name>1,1'',1''''-Phosphinothioylidynetrisaziridine</other_name>
    <other_name>Girostan</other_name>
    <other_name>N,N'', N''''-Triethylenethiophosphoramide</other_name>
    <other_name>Oncotiotepa</other_name>
    <other_name>STEPA</other_name>
    <other_name>Tepadina</other_name>
    <other_name>TESPA</other_name>
    <other_name>Tespamin</other_name>
    <other_name>Tespamine</other_name>
    <other_name>Thio-Tepa</other_name>
    <other_name>Thiofosfamide</other_name>
    <other_name>Thiofozil</other_name>
    <other_name>Thiophosphamide</other_name>
    <other_name>Thiophosphoramide</other_name>
    <other_name>Thiotef</other_name>
    <other_name>Tifosyl</other_name>
    <other_name>TIO TEF</other_name>
    <other_name>Tio-tef</other_name>
    <other_name>Triethylene Thiophosphoramide</other_name>
    <other_name>Triethylenethiophosphoramide</other_name>
    <other_name>Tris(1-aziridinyl)phosphine sulfide</other_name>
    <other_name>TSPA</other_name>
    <other_name>WR 45312</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pathological criteria, including malignant recurrent/refractory solid tumors. This&#xD;
             would include:&#xD;
&#xD;
               -  Ewing's/peripheral primitive neuroectodermal tumor (PNET)&#xD;
&#xD;
               -  Malignant peripheral nerve sheath tumor, neurofibrosarcoma&#xD;
&#xD;
               -  Rhabdomyosarcoma&#xD;
&#xD;
               -  Neuroblastoma (patients who are ineligible for tandem autologous transplant or&#xD;
                  who are at least 3 months post autologous HCT)&#xD;
&#xD;
               -  Desmoplastic small round cell tumor (DSRCT)- both new diagnoses as well as&#xD;
                  recurrent/refractory disease&#xD;
&#xD;
          -  Patients must have chemo-responsive disease, defined as; 30% or greater decrease in&#xD;
             the tumor target lesions when compared to its pre-treatment evaluation. Patients with&#xD;
             complete response will be eligible to participate&#xD;
&#xD;
          -  Available suitable HCT donor&#xD;
&#xD;
          -  Creatinine clearance or glomerular filtration rate (GFR) &gt;= 50 ml/min/1.73m^2, and not&#xD;
             requiring dialysis&#xD;
&#xD;
          -  Diffusing capacity of lung for carbon monoxide (DLCO) (corrected for hemoglobin) &gt;=&#xD;
             50% predicted. If unable to perform pulmonary function tests, then oxygen (O2)&#xD;
             saturation &gt;= 92% in room air&#xD;
&#xD;
          -  Bilirubin =&lt; 3 x upper limit of normal (ULN) and alanine aminotransferase (ALT) and&#xD;
             aspartate aminotransferase (AST) =&lt; 5 x for age (with the exception of isolated&#xD;
             hyperbilirubinemia due to Gilbert's syndrome)&#xD;
&#xD;
          -  DONOR: Matched related donor bone marrow (10 of 10 HLA alleles [HLA-A, B, C, DR, and&#xD;
             DQ]. Matched related donor peripheral blood stem cell (PBSC) is allowed only if&#xD;
             collection of bone marrow (BM) is not available or refused by parents/donor&#xD;
&#xD;
          -  DONOR: Matched allogeneic umbilical cord blood (UCB): related&#xD;
&#xD;
               -  High-resolution matching at A,B, DRB1 (minimum 4/6)&#xD;
&#xD;
               -  KIR major histocompatibility complex (MHC) class 1 preferential mismatch (minimum&#xD;
                  4/6)&#xD;
&#xD;
          -  DONOR: Matched allogeneic umbilical cord blood: unrelated&#xD;
&#xD;
               -  High-resolution matching at A,B, DRB1 (minimum 4/6) •*KIR MHC class 1&#xD;
                  preferential mismatch (minimum 4/6)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of histocompatible suitable related donor/ graft source&#xD;
&#xD;
          -  End-organ failure that precludes the ability to tolerate the transplant procedure,&#xD;
             including conditioning regimen&#xD;
&#xD;
          -  Renal failure requiring dialysis&#xD;
&#xD;
          -  Congenital heart disease resulting in congestive heart failure&#xD;
&#xD;
          -  Ventilatory failure: requires invasive mechanical ventilation&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Uncontrolled bacterial, viral, or fungal infections (currently taking medication yet&#xD;
             clinical symptoms progress); stable, controlled disease with treatment is not an&#xD;
             exclusion criteria&#xD;
&#xD;
          -  A female of reproductive potential who is pregnant, planning to become pregnant during&#xD;
             the study, or is nursing a child&#xD;
&#xD;
          -  Any patient who does not fulfill the inclusion criteria listed above&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kris M Mahadeo</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kris M Mahadeo</last_name>
    <phone>713-792-6610</phone>
    <email>kmmahadeo@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kris M. Mahadeo</last_name>
      <phone>713-792-6610</phone>
    </contact>
    <investigator>
      <last_name>Kris M. Mahadeo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>August 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive, Peripheral</mesh_term>
    <mesh_term>Nerve Sheath Neoplasms</mesh_term>
    <mesh_term>Neurofibrosarcoma</mesh_term>
    <mesh_term>Desmoplastic Small Round Cell Tumor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Nitrogen Mustard Compounds</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

